Skip to content

Study · Randomized controlled trial · n = 72 · 2018

12 results

Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.

Frøssing S, Nylander M, Chabanova E, Frystyk J, Holst JJ, Kistorp C, Skouby SO, Faber J

Diabetes, obesity & metabolism11 Aug 2017Cited by 137 (Europe PMC)

PMID28681988 (opens in a new tab)DOI10.1111/dom.13053 (opens in a new tab)PepBankPUB-28681988
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, liraglutide reduced body weight by 5.2 kg (5.6%) compared with placebo over 26 weeks.

    In plain wordsIn women with PCOS, liraglutide lowered body weight more than placebo over 26 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 72

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Measurements

    Body weight reduction
    5.2 kg
    liraglutide vs placebo

    Source sentences

    Summary
    Compared with placebo, liraglutide treatment reduced body weight by 5.2 kg (5.6%), liver fat content by 44%, VAT by 18%, and the prevalence of NAFLD by two-thirds (all P < .01).
    1 context sentence
    Summary · context
    In a double-blind, placebo-controlled, randomized clinical trial 72 women with PCOS, with a BMI > 25 kg/m2 and/or insulin resistance, were treated with liraglutide or received placebo 1.8 mg/d (2:1) for 26 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, liraglutide reduced liver fat content by 44% compared with placebo.

    In plain wordsIn women with PCOS, liraglutide lowered liver fat more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseLiver fat content
    Study

    n = 72

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Measurements

    Liver fat reduction
    44%
    liraglutide vs placebo

    Source sentences

    Summary
    Compared with placebo, liraglutide treatment reduced body weight by 5.2 kg (5.6%), liver fat content by 44%, VAT by 18%, and the prevalence of NAFLD by two-thirds (all P < .01).
    1 context sentence
    Summary · context
    In a double-blind, placebo-controlled, randomized clinical trial 72 women with PCOS, with a BMI > 25 kg/m2 and/or insulin resistance, were treated with liraglutide or received placebo 1.8 mg/d (2:1) for 26 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, liraglutide reduced visceral adipose tissue by 18% compared with placebo.

    In plain wordsIn women with PCOS, liraglutide lowered belly (visceral) fat more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseVisceral adipose tissue
    Study

    n = 72

    Comparator
    Placebo
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Measurements

    VAT reduction
    18%
    liraglutide vs placebo

    Source sentences

    Summary
    Compared with placebo, liraglutide treatment reduced body weight by 5.2 kg (5.6%), liver fat content by 44%, VAT by 18%, and the prevalence of NAFLD by two-thirds (all P < .01).
    1 context sentence
    Summary · context
    In a double-blind, placebo-controlled, randomized clinical trial 72 women with PCOS, with a BMI > 25 kg/m2 and/or insulin resistance, were treated with liraglutide or received placebo 1.8 mg/d (2:1) for 26 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, liraglutide reduced the prevalence of NAFLD by two-thirds compared with placebo.

    In plain wordsIn women with PCOS, liraglutide cut the share of women with fatty liver disease more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreasePrevalence of NAFLD
    Study

    n = 72

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, liraglutide treatment reduced body weight by 5.2 kg (5.6%), liver fat content by 44%, VAT by 18%, and the prevalence of NAFLD by two-thirds (all P < .01).
    1 context sentence
    Summary · context
    In a double-blind, placebo-controlled, randomized clinical trial 72 women with PCOS, with a BMI > 25 kg/m2 and/or insulin resistance, were treated with liraglutide or received placebo 1.8 mg/d (2:1) for 26 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, sex-hormone-binding-globulin (SHBG) levels increased by 19% with liraglutide treatment.

    In plain wordsIn women with PCOS, liraglutide treatment raised sex-hormone-binding globulin levels.

    Peptide
    Liraglutide
    Outcome
    IncreaseSHBG level
    Study

    n = 72

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Measurements

    SHBG increase
    19%
    liraglutide

    Source sentences

    Summary
    Sex-hormone-binding-globulin (SHBG) levels increased by 19% (P = .03), and free testosterone decreased by 19% (P = .054).
    1 context sentence
    Summary · context
    In a double-blind, placebo-controlled, randomized clinical trial 72 women with PCOS, with a BMI > 25 kg/m2 and/or insulin resistance, were treated with liraglutide or received placebo 1.8 mg/d (2:1) for 26 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, free testosterone decreased by 19% with liraglutide, but the change did not reach statistical significance (P = .054).

    In plain wordsIn women with PCOS, free testosterone fell with liraglutide, but the change was not statistically significant.

    Peptide
    Liraglutide
    Outcome
    No significant changeFree testosterone
    Study

    n = 72

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Measurements

    Free testosterone decrease
    19%
    liraglutide

    Source sentences

    Summary
    free testosterone decreased by 19% (P = .054).
    1 context sentence
    Summary · context
    In a double-blind, placebo-controlled, randomized clinical trial 72 women with PCOS, with a BMI > 25 kg/m2 and/or insulin resistance, were treated with liraglutide or received placebo 1.8 mg/d (2:1) for 26 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, liraglutide reduced HbA1c.

    In plain wordsIn women with PCOS, liraglutide lowered HbA1c, a measure of average blood sugar.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c
    Study

    n = 72

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    HbA1c, fasting glucose and leptin were reduced (all: P < .05)
    1 context sentence
    Summary · context
    In a double-blind, placebo-controlled, randomized clinical trial 72 women with PCOS, with a BMI > 25 kg/m2 and/or insulin resistance, were treated with liraglutide or received placebo 1.8 mg/d (2:1) for 26 weeks.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, liraglutide reduced fasting glucose.

    In plain wordsIn women with PCOS, liraglutide lowered fasting blood sugar.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting glucose
    Study

    n = 72

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    HbA1c, fasting glucose and leptin were reduced (all: P < .05)
    1 context sentence
    Summary · context
    In a double-blind, placebo-controlled, randomized clinical trial 72 women with PCOS, with a BMI > 25 kg/m2 and/or insulin resistance, were treated with liraglutide or received placebo 1.8 mg/d (2:1) for 26 weeks.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, liraglutide reduced leptin.

    In plain wordsIn women with PCOS, liraglutide lowered leptin, a fat-cell hormone.

    Peptide
    Liraglutide
    Outcome
    DecreaseLeptin
    Study

    n = 72

    Outcome group
    Adipokines · Metabolic and weight
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    HbA1c, fasting glucose and leptin were reduced (all: P < .05)
    1 context sentence
    Summary · context
    In a double-blind, placebo-controlled, randomized clinical trial 72 women with PCOS, with a BMI > 25 kg/m2 and/or insulin resistance, were treated with liraglutide or received placebo 1.8 mg/d (2:1) for 26 weeks.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, measures of insulin resistance did not change with liraglutide.

    In plain wordsIn women with PCOS, liraglutide did not change measures of insulin resistance.

    Peptide
    Liraglutide
    Outcome
    No significant changeInsulin resistance measures
    Study

    n = 72

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    whereas measures of insulin resistance, adiponectin and glucagon did not change.
    1 context sentence
    Summary · context
    In a double-blind, placebo-controlled, randomized clinical trial 72 women with PCOS, with a BMI > 25 kg/m2 and/or insulin resistance, were treated with liraglutide or received placebo 1.8 mg/d (2:1) for 26 weeks.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, adiponectin did not change with liraglutide.

    In plain wordsIn women with PCOS, liraglutide did not change adiponectin levels.

    Peptide
    Liraglutide
    Outcome
    No significant changeAdiponectin
    Study

    n = 72

    Outcome group
    Adipokines · Metabolic and weight
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    whereas measures of insulin resistance, adiponectin and glucagon did not change.
    1 context sentence
    Summary · context
    In a double-blind, placebo-controlled, randomized clinical trial 72 women with PCOS, with a BMI > 25 kg/m2 and/or insulin resistance, were treated with liraglutide or received placebo 1.8 mg/d (2:1) for 26 weeks.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, glucagon did not change with liraglutide.

    In plain wordsIn women with PCOS, liraglutide did not change glucagon levels.

    Peptide
    Liraglutide
    Outcome
    No significant changeGlucagon
    Study

    n = 72

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    whereas measures of insulin resistance, adiponectin and glucagon did not change.
    1 context sentence
    Summary · context
    In a double-blind, placebo-controlled, randomized clinical trial 72 women with PCOS, with a BMI > 25 kg/m2 and/or insulin resistance, were treated with liraglutide or received placebo 1.8 mg/d (2:1) for 26 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 3NCT05952882

Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility

Mỹ Đức Hospitaln = 188est. 1 Nov 2023 to est. 31 Dec 2025

Polycystic Ovary Syndrome · Obesity · Infertility, Female

Trial pageClinicalTrials.govUpdated 23 Oct 2023
CompletedPhase 4Results postedNCT02073929

LIPT - Liraglutide in Polycystic Ovary Syndrome

Jens Fabern = 72Mar 2014 to Dec 2015

Polycystic Ovary Syndrome · Cardiovascular Disease

Trial pageClinicalTrials.govUpdated 28 Feb 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.